ProMIS Neurosciences Announces Third Quarter 2021 Results
ProMIS Neurosciences, focusing on antibody therapeutics for neurodegenerative diseases, announced its Q3 2021 financial results. The company reported revenues of $5,101, up from zero in 2020, while operating expenses increased to $2,045,560. Net loss decreased to $961,976 from $1,564,033 year-over-year. Significant operational progress includes advancements in the PMN310 program, expected to reach IND enabling activities in H2 2022. A focus on selective antibodies for Alzheimer's and ALS underscores the company's development strategy.
- Revenue of $5,101 in Q3 2021, a significant increase from $0 in Q3 2020.
- Decreased net loss to $961,976 from $1,564,033 in the previous year.
- Progress in the PMN310 program, on track for IND enabling activities in H2 2022.
- Total operating expenses rose to $2,045,560, increasing by $481,527 year-over-year.
- Loss from operations increased to $2,040,459 from $1,564,033 in the prior year.
TORONTO and CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and nine months ended September 30, 2021.
“We are pleased to be ramping up our efforts to advance our lead asset, PMN 310, closer toward the clinic,” said Gene Williams, ProMIS’ Chairman and CEO. “The financing we secured earlier this year is enabling us to unlock the potential of our platform, which we believe could have significant impact on the treatment of several neurological diseases, including Alzheimer’s Disease (AD), Parkinson’s Disease and ALS. The strengthening of our management team and Board this quarter has also enabled us to leverage worldwide development and patent expertise and strengthen our overall competitive position.”
Corporate Highlights
- On July 2, 2021, the Company announced the voting results of its annual meeting of shareholders held on June 30, 2021, in Vancouver, British Columbia, Canada. All resolutions described in the Management Proxy Circular and placed before the meeting were approved by the shareholders.
- On July 8, 2021, the Company announced that it had filed and obtained a receipt for the Prospectus with the securities regulators in each of the provinces and territories of Canada, except Quebec.
- On August 25, 2021, we announced the closing of a public offering for gross proceeds of US
$20,125,000 (CDN$25,522,525) . - On October 7, 2021, we announced that we would hold a special general meeting of shareholders (the “Special Meeting”) on December 1, 2021. We set October 18, 2021, as the record date for the Special Meeting. The purpose of the Special Meeting is to ask shareholders to grant the Board of Directors the authority, exercisable in the Board’s discretion, to consolidate (or reverse split) the Company’s issued and outstanding common shares in furtherance of a potential listing of the Company’s shares on a stock exchange in the United States.
People
- On September 1, 2021, the Company appointed Josh Mandel-Brehm to the board of directors. Mr. Mandel-Brehm has held various key business development and operations leadership roles at leading biotechnology companies.
- On September 23, 2021, the Company appointed Maggie Shafmaster, JD, PhD, to the board of directors. Dr Shafmaster has approximately 30 years of experience providing intellectual property advice to biotechnology and pharmaceutical industries.
On October 22, 2021, the Company announced the expansion of its senior management team. The following changes were announced:
- Eugene Williams, formerly Executive Chairman, takes on the role of Chairman and Chief Executive Officer (“CEO”), with immediate effect.
- Dr. Elliot Goldstein resigned from his current role as CEO with immediate effect and continues to support us as President and special consultant to the CEO.
- Gavin Malenfant joins our senior management team as Chief Operating Officer. Mr. Malenfant brings more than 30 years of biopharmaceutical experience to our team, with special focus on providing expert management and oversight of drug development programs. The top priority in the near term will be to support the timely development of the PMN310 program to completion of IND enabling activities, anticipated in the second half of 2022. He will be working with Mr. Williams and the leadership of the PMN310 project team, whose key members include:
- Michael Grundman, MD, Senior Medical Adviser. Prior to joining the pharmaceutical industry, Dr. Grundman was Associate Director of the Alzheimer’s Disease Cooperative Study at the University of California, San Diego (“UCSD”) and is currently an Adjunct Professor of Neurosciences at UCSD. Dr. Grundman previously served on the FDA Peripheral and Central Nervous System Advisory Committee.
- Ernest Bush, PhD, Head of Pharmacology/Toxicology. Dr. Bush has 35 years of experience working in the field of biomedical research and development, driving development of innovative therapies for treatment of human diseases. He has served as a consultant in non-clinical development providing advice and insight into Investigational New Drug (“IND”) enabling programs, pre-clinical data-set analysis for due diligence and evaluation and audits of Good Laboratory Practices (“GLP”) bioanalytical and toxicology facilities and studies.
- Dennis Chen, PhD, Head of Manufacturing. Dennis has more than 25 years of prior pharmaceutical experience in working with companies from virtual to global and all phases of development. Dennis provides Regulatory Affairs, Chemistry, Chemistry, Manufacturing and Controls (“CMC”) and Biopharmaceutical Development support to ProMIS with expertise in peptides, proteins and oligonucleotides.
Financial Results
Results of Operations – Three months ended September 30, 2021 and 2020
The following table summarizes our results of operations for the three months ended September 30, 2021 and 2020:
| Three Months Ended | ||||||||||||
| September 30, | ||||||||||||
| 2021 | 2020 | Change | ||||||||||
| Revenues | $ | 5,101 | $ | - | $ | 5,101 | ||||||
| Operating expenses | ||||||||||||
| Research and development | $ | 1,192,865 | $ | 1,053,769 | $ | 139,096 | ||||||
| General and administrative | 852,695 | 510,264 | 342,431 | |||||||||
| Total operating expenses | 2,045,560 | 1,564,033 | 481,527 | |||||||||
| Loss from operations | 2,040,459 | 1,564,033 | 476,426 | |||||||||
| Other income | (1,078,483 | ) | - | (1,078,483 | ) | |||||||
| Net loss | $ | 961,976 | $ | 1,564,033 | $ | (602,057 | ) | |||||
Research and Development
Research and development expenses consist of the following:
| Three Months Ended | ||||||||||||
| September 30, | ||||||||||||
| 2021 | 2020 | Change | ||||||||||
| Direct research and development expenses by program: | $ | 590,940 | $ | 390,917 | $ | 200,023 | ||||||
| Indirect research and development expenses: | ||||||||||||
| Personnel related (including stock-based compensation) | 218,210 | 488,888 | (270,678 | ) | ||||||||
| Consulting expense | 180,604 | 73,885 | 106,719 | |||||||||
| Patent expense | 187,734 | 98,411 | 89,323 | |||||||||
| Amortization expense | 15,377 | 1,668 | 13,709 | |||||||||
| Total research and development expenses | $ | 1,192,865 | $ | 1,053,769 | $ | 139,096 | ||||||
The increase in research and development expense for the three months ended September 30, 2021, compared to the three months ended September 30, 2020, is primarily attributed to increased costs associated with external contract research organizations for internal programs of
General and Administrative
General and administrative expenses consist of the following:
| Three Months Ended September 30, | ||||||||||||
| 2021 | 2020 | Change | ||||||||||
| Personnel related (including stock-based compensation) | $ | 374,055 | $ | 242,571 | $ | 131,484 | ||||||
| Professional and consulting fees | 470,493 | 337,446 | 133,047 | |||||||||
| Facility-related and other | 8,147 | (69,753 | ) | 77,900 | ||||||||
| Total general and administrative expenses | $ | 852,695 | $ | 510,264 | $ | 342,431 | ||||||
The increase for the three months ended September 30, 2021, compared to the three same period in 2020, is primarily attributable to by an increase in share-based compensation of
Other Income
The increase in other income is primarily the change in the fair value of the derivative liability associated with the convertible debenture financing warrant liability arising from the August 2021 financing.
Results of Operations – Nine months ended September 30, 2021 and 2020
The following table summarizes our results of operations for the nine months ended September 30, 2021 and 2020:
| Nine Months Ended | ||||||||||||
| September 30, | ||||||||||||
| 2021 | 2020 | Change | ||||||||||
| Revenues | $ | 5,101 | $ | 1,578 | $ | 3,523 | ||||||
| Operating expenses | ||||||||||||
| Research and development | 2,451,985 | 2,926,242 | (474,257 | ) | ||||||||
| General and administrative | 1,554,509 | 2,051,506 | (496,997 | ) | ||||||||
| Total operating expenses | 4,006,494 | 4,977,748 | (971,254 | ) | ||||||||
| Loss from operations | 4,001,393 | 4,976,170 | (974,777 | ) | ||||||||
| Other expense | 4,857,346 | - | 4,857,346 | |||||||||
| Net loss | $ | 8,858,739 | $ | 4,976,170 | $ | 3,882,569 | ||||||
Research and Development
Research and development expenses consist of the following:
| Nine Months Ended | ||||||||||||
| September 30, | ||||||||||||
| 2021 | 2020 | Change | ||||||||||
| Direct research and development expenses by program: | $ | 1,173,873 | $ | 885,179 | $ | 288,694 | ||||||
| Indirect research and development expenses: | ||||||||||||
| Personnel related (including stock-based compensation) | 476,161 | 1,566,083 | (1,089,922 | ) | ||||||||
| Consulting expense | 370,052 | 176,898 | 193,154 | |||||||||
| Patent expense | 386,018 | 293,078 | 92,940 | |||||||||
| Other operating costs | 45,881 | 5,004 | 40,877 | |||||||||
| Total research and development expenses | $ | 2,451,985 | $ | 2,926,242 | $ | (474,257 | ) | |||||
The decrease in research and development expense for the nine months ended September 30, 2021, compared to the nine months ended September 30, 2020, reflects the conservation of cash resources and decreased contract salaries and associated costs of
General and Administrative
General and administrative expenses consist of the following:
| Nine Months Ended September 30, | ||||||||||||
| 2021 | 2020 | Change | ||||||||||
| Personnel related (including stock-based compensation) | $ | 802,356 | $ | 910,769 | $ | (108,413 | ) | |||||
| Professional and consulting fees | 950,285 | 1,083,745 | (133,460 | ) | ||||||||
| Facility-related and other | (198,132 | ) | 56,992 | (255,124 | ) | |||||||
| Total general and administrative expenses | $ | 1,554,509 | $ | 2,051,506 | $ | (496,997 | ) | |||||
The decrease for the nine months ended September 30, 2021, compared to the same period in 2020, is primarily attributable to a reduction in contracted corporate salaries and associated facility costs of
Other Expense
The increase in other expense is primarily the valuation of the derivative liability associated with the convertible debenture financing.
Outlook
Going forward we will focus on therapeutic programs in our core business area of differentiated antibodies for neurodegenerative and other mis-folded protein diseases.
PMN310, ProMIS antibody therapy selective for toxic oligomers in Alzheimer’s disease, is our highest priority. In Q3, we made significant progress, in line with plans, on all the program elements discussed in the prospectus supplement in August 2021, including cell line development, GLP toxicology work, and CMC manufacturing. We are on track to complete all IND enabling work in H2 2022.
The top priority for our scientific validation efforts, largely centered in Dr. Neil Cashman’s lab at UBC, is currently our ALS portfolio. This portfolio includes antibodies targeting mis-folded forms of TDP-43, RACK1, SOD1, and ataxin2. The most advanced of these is the program targeting TDP-43. We have initiated both in vitro assays (assessing the impact of drug on motor neuron cell lines) and in vivo (mouse model) assays and expect readouts over the next several months.
In addition, we are continuing to expand the application of our unique discovery platform, with which we can “rationally design” antibodies to be selective for only mis-folded, pathogenic proteins involved in disease. Our Chief Physics Officer, David Wishart, and his team are pursuing multiple novel targets. We have acquired access to the AlphaFold database of over 300,000 normal protein conformations, which is the starting point for our predictions of conformational epitopes on mis-folded molecular species using our proprietary computational algorithm Collective Coordinates.
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn
For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What are the financial results of ProMIS Neurosciences for Q3 2021?
How did ProMIS Neurosciences' operating expenses change in Q3 2021?
What is the focus of ProMIS Neurosciences' PMN310 program?
How much was the net loss for ProMIS Neurosciences in Q3 2021?
What recent management changes occurred at ProMIS Neurosciences?
